Servier could become the first company to bring an IDH inhibitor to market in the US for patients with myelodysplastic syndromes (MDS) next year, after the FDA started a priority review of its Tibsovo ...
Wie stark die Nutzenfiktion für Orphan Drugs ausfallen kann, wird am Beispiel des IDH1-Hemmers Ivosidenib deutlich: Bei der ...
Eine neue Analyse der deutschen Krebsregister weist unter anderem auf eine verbesserte Früherkennung und einen Rückgang ...
Treatment options for cholangiocarcinoma remain limited, particularly once the disease becomes unresectable or metastatic, and advanced disease is associated with poor survival outcomes. Although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results